Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Musculoskeletal

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 6 · 75%Moderate 1 · 12.5%High 0 · 0%

All‐cause mortality · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis

Mepolizumab showed no clear difference in mortality compared with placebo (low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
Peto OR 7.39 [0.15, 372.38]
Studies not reported
Low

Remission for at least 24 weeks · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis

Mepolizumab may leads to higher remission for at least 24 weeks compared with placebo (low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 9.5 [2.3, 39.21]
Studies not reported
Low

Durable remission · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis

Mepolizumab may leads to higher durable remission within the first 24 weeks sustained until week 52 compared with placebo (low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 13 [1.75, 96.33]
Studies not reported
Low

Relapse · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis

Mepolizumab probably leads to lower disease relapse compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 0.68 [0.53, 0.86]
Studies not reported
Moderate

Disease flare · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Any adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis

Mepolizumab showed no clear difference in any adverse event compared with placebo (low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 1.03 [0.96, 1.11]
Studies not reported
Low

Any serious adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis

Mepolizumab showed no clear difference in any serious adverse event compared with placebo (low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 0.67 [0.35, 1.28]
Studies not reported
Low

Withdrawals due to adverse events · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis

Mepolizumab showed no clear difference in any withdrawals due to AEs compared with placebo (low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 2 [0.19, 21.54]
Studies not reported
Low